The systemic hemodynamic response to a continuous 4-hour infusion of human brain natriuretic peptide (hBNP) was determined in 12 patients with advanced NYHA class III heart failure. Seven patients had ischemic cardiomyopathy, while 5 patients had idiopathic dilated cardiomyopathy. The mean (± SEM) left ventricular ejection fraction for the group was 17 ± 2% (range 14-30%). Patients were evaluated during three 4-hour study periods: baseline, hBNP infusion (0.025 or 0.05 μg/kg/min), and post-treatment (recovery). During the study periods, urinary volume losses were replaced hourly with 0.45% saline solution to separate the vasodilatory and diuretic effects of hBNP. The systemic hemodynamic effects of hBNP in these heart failure patients is shown below (mean±SEM; *p<0.05, **p<0.01 vs. baseline). hBNP 0.025 (n=6) hBNP 0.05 (n=6) Baseline hBNP Recovery Baseline hBNP Recovery RAP (mmHg) 12±2 7±1** 8±1 15±2 10±2* 14±1 PCWP (mmHg) 25±5 12±2** 18±3 29±2 18±3** 24± SVR (d·sec/cm5) 1687±206 1357±160 1737±291 1854±232 1105±193** 1332±198 CI (L/min/m2) 1.96±0.2 2.15±0.2 1.84±0.2 1.68±0.2 2.32±0.3** 2.14±0.3 HR (BPM) 78±6 84±4 86±6 92±5 86±8** 87±9 Conclusion: This first study of a steady-state infusion of hBNP in patients with heart failure demonstrates that hBNP is pharmacologically active and has potential in the treatment of heart failure.
|Original language||English (US)|
|Journal||Journal of Investigative Medicine|
|State||Published - 1996|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)